Innodem Neurosciences received $6 million to advance its digital biomarker eye-tracking technology as a possible way of diagnosing and monitoring neurodegenerative diseases. The technology is now being tested in people with multiple sclerosis (MS). Money raised by the Montreal-based startup came through a series A financing round led by Morningside Ventures. “Morningside is the ideal investor to help us transition our novel technology into a future industry standard,” Marc Reeves, Innodem’s co-founder and chief business officer, said in a…

You must be logged in to read/download the full post.